Bayer Enters $60 Million License Agreement With Atara Biotherapeutics on Cell Therapy
December 07 2020 - 1:51AM
Dow Jones News
By Cecilia Butini
Bayer AG said Monday that is has entered into an exclusive
world-wide license agreement with U.S.-based company Atara
Biotherapeutics Inc. to develop cell therapies for the treatment of
tumors with an upfront payment of $60 million.
Under the terms of the agreement, the German chemical and
pharmaceutical conglomerate will also provide Atara with milestone
payments for development, regulation and commercialization for a
total of $610 million. Bayer will also pay tiered royalties up to
low double-digit percentage of net sales, it said.
The agreement is for developing therapies for solid tumors using
chimeric antigen receptor T-cells, or CAR T-cells, meaning cells
which are specifically modified to attack cancer cells. The two
companies will particularly focus on a T-cell immunotherapy to
treat tumors such as plural mesothelioma and non-small-cell lung
cancer.
Bayer said as part of the transaction it will also reimburse
Atara on translational and clinical manufacturing services. The
German company for a limited period of time will also have
nonexclusive rights to negotiate a license for additional CAR
T-product candidates by Atara, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 07, 2020 01:36 ET (06:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Sep 2023 to Sep 2024